About the Program:
Target Audience:
This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HBV infection.
Learning Objectives:
Upon completion of the program, participants should be able to:
- Discuss how the hepatitis B virus (HBV) is transmitted in various populations
- Describe the symptoms of HBV infection
- Identify the long-term risk and consequences of untreated HBV infection
- Review the various major treatment guidelines for the diagnosis and management of patients with HBV infection
- Discuss the relative advantages and disadvantages of various antiviral treatments available for patients with HBV infection
- Describe the treatment of special populations of patients with HBV infection
Release Date: June 21, 2019
Expiration Date: June 21, 2020
Estimated time to complete each Module: 30 minutes
Media: Web
Faculty:
Douglas T. Dieterich, MD
Professor of Medicine and,
Director of CME
Department of Medicine
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Paul
J. Gaglio, MD, FACP, AGAF, FAASLD
Director;
Hepatology Outreach Center for Liver Disease and Transplantation
Professor of Medicine (in Surgery)
New York-Presbyterian Hospital
Columbia University Medical Center
New York, NY
Paul Kwo, MD
Director of Hepatology
Professor of Medicine
Stanford University School of Medicine
Palo Alto, California
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Back to Top
Joint Accreditation Statement:
|
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Back to Top
Credit Designation:
Module 1 (HBV Epidemiology and Prevention):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Natural History of Hepatitis B):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (HBV Management and Treatment):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (HBV Unique Clinical Situations):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with
high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial relationships
or relationships to products or devices they or their spouse/life
partner have with commercial interests related to the content of this
CME activity:
Doug Dieterich, MD:
- Consulting Fees: Gilead, Arbutus
|
Paul Gaglio, MD:
- Consulting Fees: Gilead, Abbvie, Salix, Dova
|
Paul Kwo, MD:
- Consulting Fees: Abbvie, Gilead, Quest
- Contracted Research: Abbvie, BMS, Gilead, Assembly
- DSMB: Janssen
|
Mark Sulkowski, MD:
- Consulting Fees: Abbott, Gilead, Arbutus
- Contracted Research:Assembly, Bio, Gilead
|
The planners and managers reported the following financial relationships
or relationships to products or devices they or their spouse/life
partner have with commercial interests related to the content of this
CME activity:
The PIM planners and managers have nothing to disclose.
Back to Top
Instructions for Participation and Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period, June 21, 2019 through June 21, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
If
you wish to receive acknowledgment for completing this activity, please
complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 14173. Upon registering and successfully completing the activity evaluation, your certificate
will be made available immediately.
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications.
The opinions expressed in the educational activity are those of the
faculty and do not necessarily represent the views of the planners.
Please refer to the official prescribing information for each product
for discussion of approved indications, contraindications, and warnings.
Back to Top
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Back to Top
Computer System Requirements
This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.
Back to Top
For CME Accreditation Questions, please click HERE
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
|